Products
Ubletamig Biosimilar Bispecific Antibody (MUC16 × CD28) for Research
Cat No.: GMP-Bios-INN-1435
Anti-MUC16/CA125 therapeutic antibody (Pre-made Ubletamig biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ubletamig (development code REGN5668) is a bispecific monoclonal antibody targeting MUC16 and CD28. It is developed by Regeneron Pharmaceuticals for Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer et al. in Phase I/II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1435-1mg | 1mg | |
| GMP-Bios-INN-1435-10mg | 10mg | |
| GMP-Bios-INN-1435-100mg | 100mg | |
| GMP-Bios-INN-1435-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ubletamig biosimilar, Bispecific mAb, Anti-MUC16/CA125;CD28 Antibody: Anti-CA125/CD28/T-cell-specific surface glycoprotein CD28/TP44 therapeutic antibody |
| INN Name | Ubletamig |
| Target | MUC16/CA125;CD28 |
| Format | Bispecific mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | TBC |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2025 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
